Testing a new drug for lupus, sjogren's, and rheumatoid arthritis
Part of Eyes & vision, Immune system & allergy, Skin clinical trials.
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 or older
- Has lupus, sjogren's disease, or rheumatoid arthritis diagnosed by a doctor
- For lupus: must have tested positive for certain antibodies (like ANA) and have had the diagnosis for at least 6 months
- For sjogren's: must have moderate to severe symptoms (score of 5 or more on two disease activity scales) and diagnosis for at least 6 months
- For rheumatoid arthritis: must have at least 6 swollen and 6 tender joints and an elevated inflammation blood test (CRP)
- No recent serious infections or planned surgery, and no significant heart rhythm problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
This study tests a new drug called HBM7020 to see how safe it is and how your body processes it. The trial includes healthy volunteers and people with autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma to understand if the drug might help reduce disease activity.
This trial tests a new drug called LY4298445 in healthy people and those with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how the body processes it.
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.